1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAmyotrophic Lateral Sclerosis Research Program is sponsored by Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). Supports research on Amyotrophic Lateral Sclerosis (ALS), a neurological disease that impacts individuals including veterans.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Amyotrophic Lateral Sclerosis Research Program, Congressionally Directed Medical Research Programs You are using an outdated browser. Please upgrade your browser to improve your experience. U.S. Department of War organization.
Due to routine system maintenance the CDMRP website will be unavailable from COB 24 April - 27 April COB.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS Transforming Health Care through Innovative and Impactful Research Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Vision – Improve outcomes and find cures for people with ALS Mission – To fund and accelerate research that translates science into effective ALS treatments » Click on Image to View Program Summary Sheet Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's disease," is a degenerative neurological disorder without a cure.
For reasons that are not well understood, the nerve cells in the brain and spinal cord that control voluntary muscle movement gradually deteriorate. ALS can be difficult to diagnose because the initial symptoms are both subtle and vague and can be attributed to a number of other conditions. Average life expectancy after diagnosis ranges between 3 to 5 years from the onset of symptoms.
It is estimated that 5-10% of all ALS cases are inherited (familial disease) while the remaining 90-95% are sporadic, with unknown etiology and risk factors. There is currently no known cure or therapy to effectively halt the progression of ALS.
Evidence from scientific research suggests a mutually inclusive relationship between ALS and military service, with a higher rate of incidence in the Veteran population, without any known reason(s) for this incidence. The ALSRP is guided by a vision to improve treatments and find cures for people with ALS.
Through its award mechanisms and funding recommendations, the ALSRP specifically supports impactful research to develop ALS treatments.
Frequently Asked Questions Application Questions Congressional Appropriations Recent Applications Recommended for Funding FY25 Peer Review Participants CDMRP Funds Research to Accelerate Treatments for Rare Diseases to Support Warfighters and their Families FY25 ALSRP Recommended for Funding List Amyotrophic Lateral Sclerosis Research Program Booklet CDMRP Supports Critical Developments in ALS, a Disease Associated with Military Service Mapping a Path Forward: Patient Involvement throughout ALS Therapeutic Development and Clinical Research Using Machine Learning for Drug Repurposing to Impact ALS Treatment The Therapeutic Potential of Metformin in ALS: Moving Through the ALSRP Pipeline from Therapeutic Development Award (TDA) to Pilot Clinical Trial Award (PCTA) Amyotrophic Lateral Sclerosis Research Program Recognized for Including Consumer Reviewers in Two-Tier Review System New Nerve-on-a-Chip System Could Revolutionize Therapeutic Development for ALS A Combined Cell and Gene Therapy Approach for Preserving Motor Neuron Function in ALS Matt Bellina: "ALS is a worthy adversary, but each day I am hopeful."
Improving the Effective Bioavailability of ALS Therapeutics Click here to provide feedback/comments to the ALSRP Last updated Thursday, July 16, 2026
According to the current listing, eligibility includes: Eligibility depends on the individual CDMRP announcement and subsequent funding line. Solicitations specify the minimum qualifications. Generally open to research institutions, for-profit businesses, and universities. Confirm the full requirements in the official notice before applying.
Amyotrophic Lateral Sclerosis Research Program is funded by Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article